Abstract
We have recently shown that the LTB 4 Our studies provide novel insights into the LTB 4 -BLT1 lipid chemoattractant pathway in human T-cell responses, and how it may link innate and adaptive immunity.
Introduction
Recently, novel roles for bioactive lipids, such as the leukotrienes and sphingosines, in immune cell trafficking and regulation have been elucidated 1 . A key feature of bioactive lipid chemoattractants is the rapidity with which they are produced as they are synthesized in minutes as opposed to the hours required to synthesize peptide chemoattractants 2, 3 . Leukotriene B 4 (LTB 4 ) is one such molecule derived by 5-lipoxygenation of arachidonic acid in activated innate leukocytes at inflammatory sites 4 .
LTB 4 mediates its activity via two G protein-coupled seven transmembrane spanning receptors named BLT1 and BLT2 5, 6 . BLT1 is the high-affinity receptor and is preferentially expressed on peripheral leukocytes, while BLT2 is a lower affinity receptor expressed more ubiquitously.
Since discovery in 1982, LTB 4 has been a known potent chemoattractant for myeloid cells 4, 5, 7 . Nevertheless, it has recently been appreciated that LTB 4 is also a potent chemoattractant for effector T-cells [8] [9] [10] . We have recently described that BLT1 mRNA is highly expressed in mouse effector T-cells, and LTB 4 potently induces their firm adhesion and chemotaxis 8 . Although mouse BLT1 protein levels have not been characterized, we have shown that the LTB 4 -BLT1 pathway performs an important function recruiting early effector T-cells to sites of antigen re-challenge using BLT1-deficient mice in an active immunization model of asthma.
Nevertheless, little is known as to how these findings in mice can be extended to human T-cell trafficking or disease pathogenesis. Prior to the identification of BLT1, it was only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From shown that LTB 4 bound a small proportion of human peripheral blood T-cells 11, 12 , and could induce their chemotaxis both in vitro and in vivo after topical application of LTB 4 11,13 . Studies have noted very low level expression of BLT1 in human peripheral blood T-cells as measured by RNA levels or cell surface protein expression 14, 15 . The phenotype and function of human BLT1 + T-cells and the functional significance of the LTB 4 -BLT1 lipid chemoattractant pathway in human adaptive immune cell trafficking, therefore, still remain to be defined.
A cardinal feature of adaptive immunity is the ability to mount swift recall responses to cognate antigen challenge 16, 17 . To implement effector functions, naïve and memory Tcells are first activated by cognate antigen presenting cells, usually in lymphoid organs, and then home to tissue sites of inflammation 18, 19 . Based on CCR7 mediated lymphoid homing, memory cells have recently been broadly defined as CCR7 + central memory, and CCR7 -effector memory populations 20 . However, in part because of the stochastic nature of in vivo priming events and antigen re-exposure at different tissue sites, memory T-cells are a very heterogeneous population [21] [22] [23] [24] . Thus memory T-cells exist across a broad spectrum with regard to phenotype, function and differentiation.
Signals regulating T-cell activation or differentiation are also tightly linked to the expression of specific chemokine receptors involved in T-cell trafficking 25, 26 .
In fact, distinct patterns of responsiveness to migratory cues have helped define the function of different memory/effector T-cell subsets both in terms of differentiation stage, as well as tissue localization and cellular interactions. Subsets of memory/effector T- 
Materials and Methods

Study Subjects
Atopic asthmatics were identified by skin testing to cat allergen. Bronchoalveolar lavage (BAL) cells and PBMC samples were obtained from cat allergen-sensitive atopic asthmatics as described 28 . Normal BAL were obtained from healthy lung transplant donors. Donors were studied in the acute and chronic/latent phases of EBV infection.
PBMC were obtained from healthy volunteers or fresh buffy coats from the Massachusetts General Hospital blood bank. All human subject protocols were approved by the Institutional Review Board. Informed consent was obtained from all study participants.
Cell preparation and culture
PBMC were prepared by density gradient centrifuge on Histopaque-1077 (SigmaAldrich, St. Louis, MO). Untouched CD4 + T-cells and CD8 + T-cells, and CD45RA + / CD45RO + CD4 + or CD8 + T-cells were isolated using magnetic bead-depletion (Miltenyi Biotec, Auburn, CA). Dendritic cells (DCs) were prepared from fresh buffy coats as previously described 29 . CD4 + or CD8 + T-cells were cultured with DC's as described 30 .
γδ and NKT cell cultures were obtained by labeling fresh PBMC with flourochromeconjugated γδ and Vα24 antibodies, magnetic bead positive selection (Miltenyi) and activation with 2 ug/ml PHA. PB CD1d-restricted NKT cells clones were generated from healthy donors as previously described 31, 32 . BAL cells were isolated by passing BAL through gauze to remove mucus, then washed and resuspended in 1% FCS PBS. 
CD45RA (HI100), γδ (Β1), perforin (27-35) and 6B11 were purchased from BD PharMingen (San Diego, CA). Abs to CX3CR1 (2A9-1) was purchased from MBL (Nakaku Nagoya, Japan), CD57 (NC1) and Vα24 (C15) were purchased from Beckman Coulter (Fullerton, CA (Fig. 1a) .
A substantial fraction of PB NKT and γδ T-cells display surface BLT1 in healthy donors
We also characterized BLT1 expression on innate lymphocytes. In contrast to conventional αβ T-cells, a much larger fraction of these T-cells display surface BLT1 in healthy individuals (Fig. 1a) . 5±4% SD (range 0.9-11.1%, n=7) of PB γδ T-cells display surface BLT1. Rare CD1d-restricted NKT cells were identified directly from PBMC by dual staining of a canonical TCR rearrangement using antibodies specific for the TCR Vα24 chain and the invariant Vα24JαQ (6B11). We found that 13±22% SD (range 0-64%, n=10) of PB NKT cells express surface BLT1. 
PB FSC hi T-lymphocytes of healthy donors are enriched for BLT1 mRNA
BLT1 is preferentially expressed on pre-terminally differentiated antigen-primed PB Tcells in health
To further characterize this BLT1-enriched population, we examined cell surface markers associated with memory and effector T-cell differentiation. We find that PB BLT1 + Tcells are mostly antigen experienced CD45RO + cells (Fig. 2a) 36, 37 . However, recently a novel role for CD38 in leukocyte migration has been elucidated 38, 39 , which demonstrated that CD38 enhances chemotactic responsiveness and inflammatory tissue entry of dendritic cells 39 .
PB BLT1 + T-cells are enriched for a subset of inflammatory chemokine receptors associated with memory/effector T-cells in healthy donors
We next studied surface chemokine receptor co-expression to glean insight into tissue localization and cellular interactions of BLT1 + T-cells, and the temporal patterns in which they might execute effector functions ( Fig. 3 only.
For In chemotaxis assays (Fig. 4e) 
In vitro primed effector T-cells transiently upregulate surface BLT1
As only a small fraction of PB T-cells express BLT1 during health, we wanted to determine if BLT1 expression could be induced during active inflammation. We found that BLT1 is most robustly induced by priming naïve (CD45RO In a representative example in Fig. 5 , a striking 38% of in vitro activated effector CD4 + T-cells (Fig. 5a , bottom left panel) and 39% of effector CD8 + T-cells were induced to express surface BLT1 (Fig. 5b) . In vitro activated effector T-cells also chemotax to LTB 4 , and this chemotaxis was abrogated by the specific LTB 4 receptor antagonist CPonly.
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BLT1 is not stably expressed on in vitro activated T-cells. It is transiently expressed between days 6-10 of activation, peaking at day 8, and subsequently undergoes downregulation. Furthermore, we failed to see BLT1 surface expression or ligand responsiveness on several T-helper and CTL lines or clones, maintained in long-term culture by several rounds of re-stimulation (data not shown).
In vitro activated innate T-cells upregulate surface BLT1
We found when activated in vitro, BLT1 surface expression is also dramatically upregulated on innate γδ T-cells and NKT cells (Fig. 5e ). When Miltenyi bead purified γδ and Vα24 cells were activated with PHA, BLT1 surface expression started to increase by day 4. Furthermore, BLT1 expressed on re-stimulated NKT clones demonstrated functional responsiveness to LTB 4 by calcium flux (Fig. 5f ), as well as chemotaxis (data not shown).
BLT1 + memory/effector T-cells are present in the lungs of asymptomatic asthmatics
The ability to rapidly secrete T-cell effector cytokines when activated and the marked coexpression of inflammatory chemokine receptors suggest that PB BLT1 + T-cells may migrate into peripheral tissues to perform effector functions. We studied surface BLT1 expression on tissue-infiltrating lymphocytes freshly isolated from bronchoalveolar only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From lavage (BAL) samples obtained from asymptomatic asthmatics (Fig. 6 ). BLT1 + T-cells were enriched in the BAL compartment compared to simultaneously obtained blood samples in these subjects. Fig. 6a is a representative example in which blood and BAL T-cell BLT1 expression is compared. Blood and BAL total T-cell and BLT1 + T-cell phenotype are compared in Fig. 6b , and demonstrate that BAL resident T-cells are mostly memory in phenotype. BLT1 surface expression was significantly increased on both BAL memory CD4 + T-cells (p=0.042) and CD8 + T-cells (p=0.034) compared to blood Tcells (Fig. 6c) .
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During acute EBV infection BLT1 surface expression is dramatically increased on activated tetramer + CD8 + T-cells
To further define the role of BLT1 during inflammation in humans, we studied surface BLT1 expression on antigen-specific effector CD8 + T-cells generated during the primary immune response to Epstein-Barr virus (EBV) (Fig. 7) . In individuals with acute EBV infection, unlike in healthy individuals, a substantial number of activated blasts are present in the FSC hi gate in PB (Fig. 7a) . In Fig. 7a, using For 39 . Thus, CD38 may also be a marker of blood T-cells endowed with enhanced chemotactic responsiveness to chemokine ligands for which they bear receptors. and CXCR5 identify functional subsets within the human CD4 + central memory pool 24 .
only.
For Freshly isolated BLT1 + T-cells from blood were analyzed for co-expression of chemokine receptors by flow cytometry.
These data are from five to six independent experiments. only.
